Moxibustion Plus Cupping in Convalescent Patients With COVID-19

Not Applicable

• Conditions: Convalescence; COVID-19
• Interventions: Other: Moxibustion plus Cupping

• Registration Number: NCT04374084
• Lead Sponsor: Guang'anmen Hospital of China Academy of Chinese Medical Sciences

Brief Summary

This trial is designed to evaluate the efficacy and safety of moxibustion plus cupping in the convalescence of COVID-19.

Detailed Description

Moxibustion plus cupping may be effective and safe for convalescent patients with COVID-19, but evidence is limited. The randomized clinical trial may help to provide evidence-based factors for improving the patients' symptoms in the convalescence of COVID-19.

Study Timeline

• Study First Submitted: 2020-04-20
• Study First Submitted QC: 2020-05-02
• Study First Posted: 2020-05-05
• Study Start: 2020-05-10
• Status Verified: 2021-08
• Last Update Submitted: 2021-11-16
• Last Update Posted: 2021-11-24
• Primary Completion: 2021-12
• Study Completion: 2021-12

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

1. Clinical diagnosis of the convalescence of COVID-19 (defined by the Chinese Guideline for COVID-19 in 2020 Trial Version 7).
2. 18-70 years old;
3. chest tightness/fatigue/shortness of breath/cough, with at least 2 of the above symptoms and the average VAS score (last 48 hours) ≥ 40 points;
4. Volunteers with informed consent;

Exclusion Criteria

1. Surgery in the lung that affects lung function;
2. Rely on mechanical ventilation to maintain lung function;
3. Chronic lung diseases affecting lung function;
4. Diseases affecting heart function;
5. Severe basic diseases;
6. Resting heart rate > 120/min, systolic blood pressure > 180mmHg, diastolic blood pressure > 100mmHg;
7. Unstable angina or myocardial infarction in the past 1 month;
8. Severe obesity (BMI>30kg/m2);
9. Allergic constitution;
10. Pregnant or lactating women;
11. Disabled patients;
12. Mentally ill Patients;
13. Participating in other clinical trials;
14. Poor compliance or other complicate conditions according to the researchers.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Moxibustion plus Cupping	Moxibustion plus Cupping	Moxibustion plus cupping and basic therapy (rehabilitation direction and basic breathing exercise) once a day for 4 weeks (28 sessions).The moxibustion plus cupping treatments were divided into 2 alternating formulas: A: Monday, Wednesday, Friday and Sunday: moxibustion on bilateral Fengmen (BL12), Feishu (BL13) and Pishu(BL20) B: Tuesday, Thursday and Saturday: moxibustion on Zhongwan (RN12), Qihai (RN6), bilateral Tianshu(ST25) and Zusanli(ST36) + cupping on bilateral Feishu(BL13) Geshu(BL17) Pishu(BL20) The 2 formulas were used alternatively every other day, 7 times per week, for 4 weeks. Moxibustion acupoint addition: profuse sweating added Fuliu (KI7), insomnia added Shenmen(HT7) anxiety or depression added Neiguan (PC6).

Primary Outcome Measures

Name	Time	Method
The proportion of responder at week 4	baseline, week 4	The responder is defined as the participants with ≥ 50% average VAS decrease of chest tightness and fatigue compared with baseline. The VAS ranges from 0 to 100.

Secondary Outcome Measures

Name	Time	Method
The change of the walking distance of six-minute-walking test from baseline	baseline, week 4, week 8	At the end of week 4 and week 8, the walking distance of six-minute-walking test changed from baseline.
The change of the lowest oxygen saturation of six-minute-walking test from baseline	baseline, week 4, week 8	At the end of week 4 and week 8, the lowest oxygen saturation of six-minute-walking test changed from baseline.
The proportion of patients in recovery of pulmonary function at week 4	baseline, week 4	At the end of week 4, the proportion of patients in recovery of pulmonary function in all participants.
The proportion of responder at week 8	baseline, week 8	The responder is defined as the participants with ≥ 50% average VAS decrease of chest tightness and fatigue compared with baseline. The VAS ranges from 0 to 100.
The change in the average VAS score of main symptoms from baseline	baseline, week 4, week 8	At the end of week 4 and week 8, the change in the average VAS score of main clinical symptoms (chest tightness, fatigue, short of breath and cough) will be assessed from baseline. VAS ranges from 0-100.
The change in the average VAS score of other symptoms from baseline	baseline, week 4, week 8	At the end of week 4 and week 8, the change in the average VAS score of other symptoms (insomnia, sweating, mental fatigue, inappetence, mental stress) will be assessed from baseline. VAS score ranges from 0-100.
The change in mean frequency of diarrhea and spontaneous bowel movements from baseline	baseline, week 4, week 8	At the end of week 4 and week 8, the change in mean frequency of diarrhea and spontaneous bowel movements in the past 1 week will be assessed from baseline.
The proportion of participants with ≥50%/75% improvement of VAS from baseline	baseline, week 4, week 8	At the end of week 4 and week 8, the proportion of participants with ≥50%/75% VAS change of clinical symptoms (chest tightness, fatigue, short of breath, cough, insomnia, sweating, mental fatigue, inappetence, mental stress) will be assessed. VAS score ranges from 0-100.
The change of the SDS score from baseline	baseline, week 4, week 8	At the end of week 4 and week 8, the Self-Rating Depression Scale (SDS) score changed from baseline.The standard SAS ranged from 25 to 100 with higher score as the worse depression.
The change in the severity VAS score of main symptoms from baseline	baseline, week 4, week 8	At the end of week 4 and week 8, the change in the severity VAS score of main clinical symptoms (chest tightness, fatigue, short of breath and cough) will be assessed from baseline. VAS score ranges from 0-100.
The proportion of patients whose lung CT return to normal at week 4	baseline, week 4	Lung CT shows complete absorption of inflammation.
The change of the SAS score from baseline	baseline, week 4, week 8	At the end of week 4 and week 8, the Self-Rating Anxiety Scale (SAS) score changed from baseline. The standard SAS ranged from 25 to 100 with higher score as the worse anxiety.
The change of the WHO QOL-BREF score from baseline	baseline, week 4, week 8	At the end of week 4 and week 8, the WHO Quality of Life-BREF (WHO QOL-BREF) score changed from baseline. WHO QOL-BREF ranged from 4 to 20 with higher scores as the better quality of life.
The change of the blood CRP/LYMPH#/NEUT% value from baseline	baseline, week 4	At the end of week 4, the blood C-reactive protein (CRP) value, blood lymphocyte count (LYMPH#) and the percentage of blood neutrophils (NEUT%) value will be assessed compared with baseline.
subtype analysis	baseline, week 4	Subtype analysis of age (≤40 years old, \>40 years old), gender (male, female), and severity of the disease (mild, moderate, heavy, critical) will be performed in the primary outcome.

Trial Locations

Locations (1)

Hubei Province Hospital; 🇨🇳 Wuhan, Hubei, China